Public Comments to CIRM Application Review Subcommittee Meeting on May 30

Public Comments to CIRM Application Review Subcommittee Meeting on May 30

The hypocrisy and double standards of CIRM are overwhelmingly highlighted in CIRM awards and press releases. The conflicts of interest (COI) of CIRM are distinctly demonstrated in CIRM awards and press releases. In CIRM program announcements, on CIRM website, CIRM, a California State Agency and a California Stem Cell Agency, clearly states that “The mission of CIRM is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world”. CIRM guidelines and instructions also unambiguously state “CIRM considers regenerative medicine to mean therapeutic approaches that are intended to replace, regenerate or repair the function of aged, diseased, damaged or defective cells, tissues, and/or organs”. However, not even one award in this round of CIRM press release could provide any therapeutic approach to replace, regenerate or repair the function of aged, diseased, damaged or defective cells, tissues, and/or organs. It is utterly disgusting that, despite Prop14 prohibits ICOC members from using their official positions to influence the CIRM award process in any way for their ties, all CIRM ICOC Vice Chair Maria Bonneville, a California State employee, does is to display her COI to CIRM awards in public by floating her scientifically fraudulent awards to the top lists of CIRM awards again and again to enrich her close ties with tens of millions of California taxpayer dollars, instead of doing her job to deliver the promise of the California Stem Cell Research and Cures Act for California voters. It is utterly disgusting that CIRM COI intentionally set hurdles to make our application TRAN4-16090 “Defined Human Embryonic Stem Cell (hESC) Platform Enabling Large Scale Manufacturing of Clinical-Grade Cardiomyocytes for Heart Regenerative Therapy and Biofabrication”, which does provide a breakthrough therapeutic approach to replace, regenerate or repair the function of diseased or damaged hearts and aligns with CIRM’s mission, not even eligible for applying for CIRM TRANS, and deliberately block hESC medical innovations to reach patients who urgently need them. It is utterly disgusting that, instead of awarding projects that could deliver transformative regenerative medicine treatments for heart disease and failure like our TRAN4-16090, CIRM actually gave $6 million of taxpayer dollars to an UCLA scam project to use monoclonal antibody to attack the body’s healing and regenerative system directly linked to ICOC board member Shlomo Melmed. It is utterly disgusting that Irving Weissman’s scam projects of his Company Stem Cell and Forty Seven and TRAN4-16091 of purifying HSC that neither deliver transformative regenerative medicine treatments nor do it in an equitable manner to a diverse California and the world could actually make to the top list of CIRM awards again and again to make the investors and CA taxpayers have to eat billions of losses, while he and Stanford University have indeed profited hundreds of millions.

Public Comments to CIRM Application Review Subcommittee Meeting on May 30

Dear CIRM ARS,

Thanks for the meeting notice and thank you for this opportunity to present my Public Comment.

Lack of a scalable human cardiac stem cell source with adequate heart muscle regeneration potential remains a major setback for heart replacement, and fabricating a human heart is still beyond reach. San Diego Regenerative Medicine Institute (SDRMI) PluriXcel-SMI-Heart Platform enables direct conversion of pluripotent human embryonic stem cells (hESC) uniformly into a large supply of human cardiac stem or precursor cells for heart replacement or bio-fabrication [patent: USPTO# 9,428,731], providing a practical scalable solution for heart regeneration. More about the innovative hESC technology platforms that have overcome some major bottlenecks or hurdles in the regenerative medicine market can be found on our websites https://www.sdrmi.org & https://www.plurixcel.com.

Could you please explain to the diverse California and the world why our application TRAN4-16090 “Defined hESC Platform Enabling Large Scale Manufacturing of Clinical-Grade Cardiomyocytes for Heart Regenerative Therapy and Biofabrication” is not even eligible for applying for CIRM TRANS even though it is translational by nature, urgently needed stem cell technology to address major bottleneck in regenerative medicine, completely meets CIRM TRAN4 eligibility criteria, and aligns with CIRM’s mission “to accelerate world-class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and the world” (Please also see my previous comments at ICOC meeting on our websites https://www.sdrmi.org & https://www.plurixcel.com), and why those projects to neither deliver transformative regenerative medicine treatments nor do it in an equitable manner to a diverse California and the world actually made to the top list of CIRM awards, just because they do have a lot of conflict of interests (COI) to tout for them, including Harvard professors and former ISSCR presidents, as demonstrated by a flood of Letters to the Board. Could you please explain to the diverse California and the world why CIRM, a California stem cell agency, would not support hESC medical innovations to reach patients who urgently need them, keep letting such crucial innovations of EDWO small business get triaged by COI of CIRM against CIRM’s commitment to DEI and inclusive excellence, instead let taxpayer dollars to fuel adult stem cell scams, like iPSC Ponzi scheme of skin cells reprogrammed with oncogenes, spread all over the diverse California and the world (Please see below: Aspen Neuroscience and Ryne Bio/Kenai Therapeutics used plagiarized preclinical animal safety and efficacy data of the hESC products to obtain FDA approval and CIRM awards for iPSC products). More about the manufacturing process of the scarlet “Red” iPSC Ponzi scheme of the Bush Administration and those behind it who colluded to profit from government funding and private investment can be found on our websites https://www.sdrmi.org & https://www.plurixcel.com.

One of the fatal flaws of immunotherapy that none of the immuno-oncology companies would tell the public is that immunotherapy is extremely ineffective, only kills < 1% of cancer cells, and cancers are well known for reoccurrence if only one cancer cell is not killed. Irving Weissman, the Stem Cell Center Director of Stanford University, of course knows that, and of course he also knows the basic scientific facts that CD47 – the “do not eat me” signal -- is a common cell surface ligand expressed on both healthy and cancer cells, and CD47 antibody attacks not only cancer cells, but also stem cells of vital organs, making it highly toxic to patients. However, he still had CIRM former President back his Company Forty Seven with $15 million of taxpayer money, which allowed him to sell Forty Seven to Gilead Sciences for $4.9 billion that had generated $67 million for Stanford and $191 million for himself in March 2020. In July 2023, Gilead Sciences had to eat the loss of $4.9 billion and end Phase 3 trial of the CD47 antibody of Forty Seven since it is unlikely to improve survival, after multiple clinical holds for over a year, which have raised some serious questions about how Forty Seven could even pass Phase 1 safety trial with the $15 million from CIRM if they did not falsify or fabricate data in CIRM-funded research and clinical trials, after previous $40 million from CIRM to Irving Weissman’s other Company Stem Cell without any competition had produced absolutely nothing. Of course, the public would not hear anything even slightly mentioned about such failed clinical trials that CIRM has pumped into hundreds of millions of taxpayer dollars in CIRM press releases, and CA taxpayers end up having to eat the losses too. Who have actually profited from the loss of taxpayer dollars, profited from deliberately harming patients, profited from intentionally defrauding the investing public in the staggering amounts of hundreds of millions, even billions? Could you please explain to the diverse California and the world why Irving Weissman’s scam projects of his Company Stem Cells and Forty Seven and TRAN4-16091 of purifying HSC that neither deliver transformative regenerative medicine treatments nor do it in an equitable manner to a diverse California and the world could actually make to the top list of CIRM awards again and again to make the investors and CA taxpayers have to eat billions of losses, while he and Stanford University have indeed profited hundreds of millions?